In this issue:
- Osimertinib trough concentration and clinical response
- Uncommon EGFR mutations and osimertinib efficacy
- An investigational delta-like ligand-targeting agent
- Efficacy and safety of nivolumab plus ipilimumab
- Interstitial pneumonitis and immunotherapy
- Survival with durvalumab after chemoradiotherapy
- Patient-reported outcomes with immunotherapy and chemotherapy
- Disease stage shift and survival
- Epidemiology of lung cancer in never smokers
Please login below to download this issue (PDF)